Editor profile
Director, International Health Policy
Sophia Rossi monitors global healthcare regulations, insurance reimbursement models, and digital health compliance. She specializes in the evolving regulatory frameworks of the EMA and FDA.
sophia.rossi@medtechdaily.orgHeidi Health's "Pressure Points 2026" report shows that 83% of clinicians have already adopted ambient AI documentation tools on their own before their institutions establish formal AI governance frameworks, in response to the growing burden of medical documentation.
A study by the American Medical Association shows that most doctors believe data from consumer wearable devices (such as smartwatches) have clinical value, but issues such as accuracy, liability, and data integration still hinder their widespread adoption.
Analyze the event of Veradigm being sued for patient portal data tracking, and explore the challenges and industry impacts of medical technology companies in data sharing and privacy compliance.
In the third quarter of 2026, the FDA will make approval decisions on multiple biotechnology products, involving areas such as IgA nephropathy, mRNA influenza vaccines, Duchenne muscular dystrophy cell therapy, and gene therapy. These decisions will profoundly impact the direction of the medical technology industry.
ZS Impact Institute report shows 90% of consumers trust AI health advice as much as that of doctors, early diagnosis could save $500 billion, promoting a zero-distance care model.
2026 US Digital Health Laws and Regulations Update, covering digital health technology, data use and sharing, and analysis of impacts on medical technology companies, hospitals, and investors.
GE HealthCare will showcase AI software, imaging systems, radiopharmaceuticals, and localized production solutions related to nuclear medicine during SNMMI 2026, reflecting that nuclear medicine is moving from competition among single devices toward a phase of expansion driven by “platformization + ecosystemization.”
Siemens Healthineers is partnering with AiM Medical Robotics to integrate MRI scanning with a neurosurgical robotic platform; meanwhile, Procept BioRobotics has completed enrollment in a randomized study on prostate cancer. Together, these two developments point to a trend: medical device companies are accelerating their entry into more high-barrier treatment settings through image guidance, robotic systems, and clinical trials.